Skip to main content
NewslettersWatchlist

Sanofi-Aventis S.A. ADR(SNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low57.47
Day High57.96
Open:57.95
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection
Newswire.ca
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
Reuters
New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial
Motley Fool
Should You Buy Novavax Stock After This Regulatory Win?
Barchart
You Can Stop Looking, Here's the Perfect Stock for the Current Market
Motley Fool
Why Sanofi Stock Was Robustly Healthy Today
Motley Fool
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
Investor Brand Network
Annovis Bio (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
GlobeNewswire
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Motley Fool
Where Will Novavax Be in 5 Years?
Motley Fool
Sanofi (SNY) Q2 2024 Earnings Call Transcript
Motley Fool
25 Best Artificial Intelligence Stocks to Buy Right Now
Motley Fool
Where Will Novavax Be in 1 Year?
Motley Fool
Is It Too Late to Buy Novavax Stock?
Motley Fool
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
Motley Fool
Why Vaccine Stocks Rallied This Week
Motley Fool
3 Things You Need to Know If You Buy Novavax Today
Motley Fool
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
Motley Fool
Could Novavax Become the Next Moderna?
Motley Fool
Novavax Stock Just Tripled. Is It Too Late to Buy?
Motley Fool
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?
Motley Fool
Why Novavax Stock More Than Doubled Today

Profile

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.